299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details
臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02265679 (ClinicalTrials.gov) | October 2001 | 15/10/2014 | Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients | A Randomized, Double-blind Within Dose, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis Patients | Cystic Fibrosis | Drug: BIIL 284 BS, low dose, pediatric patients;Drug: BIIL 284 BS, medium dose, pediatric patients;Drug: BIIL 284 BS, high dose, pediatric patients;Drug: BIIL 284 BS, low dose, adult patients;Drug: BIIL 284 BS, medium dose, adult patients;Drug: BIIL 284 BS, high dose, adult patients;Drug: Placebo | Boehringer Ingelheim | NULL | Completed | 6 Years | N/A | Both | 45 | Phase 1 | NULL |